Using continuous glucose monitors to improve care for type 2 diabetes
The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Early Onset and Late Onset Type 2 Diabetes: an Effectiveness - Implementation Type Ⅱ Hybrid Design Quasi-experimental Pragmatic Trial
This project will see if continuous glucose monitors help adults with type 2 diabetes in community clinics in Ningbo manage blood sugar better than standard fingerstick monitoring.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Academic / other |
| Locations | 2 sites (Ningbo, Zhejiang and 1 other locations) |
| Trial ID | NCT07097415 on ClinicalTrials.gov |
What this trial studies
This is a pragmatic, quasi-experimental effectiveness‑implementation (Type II hybrid) trial carried out at two community health centers in Yinzhou District, Ningbo. About 800 adults with established type 2 diabetes will be randomly assigned to either continuous glucose monitoring (CGM) with device training or usual self‑monitoring of blood glucose. The trial measures both clinical outcomes (blood glucose control, hypoglycemia) and implementation outcomes (device use, data transmission, clinic workflow). The goal is to test CGM performance and how well it can be integrated into routine community healthcare.
Who should consider this trial
Good fit: Adults (age ≥18) with a documented diagnosis of type 2 diabetes for at least one year who are registered residents receiving care at the participating community health centers in Yinzhou District, Ningbo.
Not a fit: People with type 1 or other non‑type 2 diabetes, pregnant women, those taking hormonal drugs that affect blood sugar, or patients with severe kidney or liver dysfunction or active cancer are not eligible and are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, CGM could improve glucose control, reduce episodes of hypoglycemia, and make diabetes care more proactive and efficient in community clinics.
How similar studies have performed: Prior trials have shown CGM can improve glucose control and reduce hypoglycemia in people with type 2 diabetes—especially those on insulin—while embedding CGM into community primary‑care settings in China remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ① Age ≥ 18 years old; ② There is a previous diagnosis of T2DM in the electronic medical record system of Qianhu Hospital and Fuming Street Community Health Service Center, and the diagnosis has been made for 1 year or more; ③ Resident with permanent registered residence registration who has filed in the health records of residents in Yinzhou District. Exclusion Criteria: * ① Pregnant women; ② Type 1 diabetes, adult latent autoimmune diabetes, special type diabetes (such as post pancreatic surgery, monogenic diabetes); ③ Patients who are currently using or have previously used hormone drugs that may affect blood sugar levels; ④ Patients with severe renal insufficiency (eGFR\<30ml/m \^ 2, or undergoing hemodialysis); ⑤ Patients with severe liver dysfunction (ALT or AST greater than 3 times the upper limit of normal); ⑥ Tumor patients.
Where this trial is running
Ningbo, Zhejiang and 1 other locations
- Qianhu Hospital — Ningbo, Zhejiang, China (Recruiting)
- Fuming Street Community Health Service Center — Ningbo, China (Recruiting)
Study contacts
- Study coordinator: Yunxiao Wu
- Email: 2411110188@pku.edu.cn
- Phone: +8618811381925
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.